• 1
    Mast EE, Margolis HS, Fiore AE, Brink EW, Goldstein ST, Wang SA, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep 2005; 54: 131.
  • 2
    Lok AS. Chronic hepatitis B. N Engl J Med 2002; 346: 16821683.
  • 3
    de Franchis R, Hadengue A, Lan G, Lavanchy D, Lok A, McIntyre N, et al. EASL Jury. EASL International Consensus Conference on hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J Hepatol 2003; 39( Suppl 1): S3S25.
  • 4
    Keeffe EB, Dieterich DT, Han SB, Jacobson IM, Martin P, Schiff ER, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol 2006; 4: 936962.
  • 5
    ACT-HBV Asia-Pacific Steering Committee Members. Chronic hepatitis B: treatment alert. Liver Int 2006; 26: 4758.
  • 6
    Lok AS, McMahon BJ. Chronic hepatitis B. HEPATOLOGY 2007; 45: 507539.
  • 7
    Tong MJ, Blatt LM, Tyson KB, Kao VWC. Death from liver disease and development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection: a prospective study. Gastroenterol Hepatol 2006; 2: 4147.
  • 8
    Yeh SH, Tsai CY, Kao JH, Liu CJ, Kuo TJ, Lin MW, et al. Quantification and genotyping of hepatitis B virus in a single reaction by real-time PCR and melting curve analysis. J Hepatol 2004; 41: 659666.
  • 9
    Kao JH, Chen PJ, Lai MY, Chen DS. Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology 2003; 124: 327334.
  • 10
    Kao JH, Wu NH, Chen PJ, Lai MY, Chen DS. Hepatitis B genotypes and the response to interferon therapy. J Hepatol 2000; 33: 9981002.
  • 11
    Tong MJ, Blatt LM, Kao JH, Cheng JT, Corey WG. Precore/basal core promoter mutants and hepatitis B viral DNA levels as predictors for liver deaths and hepatocellular carcinoma. World J Gastroenterol 2006; 12: 66206626.
  • 12
    De Jongh FE, Janssen HLA, De Man RA, Hop WCJ, Schalm SW, Van Blankenstein M. Survival and prognostic indictors in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992; 103: 16301635.
  • 13
    Di Marco V, Lo Iacono O, Camma C, Vaccaro A, Giunta M, Martorana G, et al. The long-term course of chronic hepatitis B. HEPATOLOGY 1999; 30: 257264.
  • 14
    Realdi G, Fattovich G, Hadziyannis S, Schalm SW, Almasio P, Sanchez-Tapias J, et al. Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. J Hepatol 1994; 21: 656656.
  • 15
    Fattovich G. Natural course and prognosis of chronic hepatitis type B. J Viral Hepatol 1996; 2: 263276.
  • 16
    Liaw YF, Tai DI, Chu CM, Chen TJ. The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. HEPATOLOGY 1988; 8: 493496.
  • 17
    Lo KJ, Tong MJ, Chien MC, Tsai YT, Liaw YF, Yang KC, et al. The natural course of hepatitis B surface antigen-positive chronic active hepatitis in Taiwan. J Infect Dis 1982; 146: 205210.
  • 18
    Cirrhosis Asian Lamivudine Multicentre Study Group. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 15211531.
  • 19
    Perrillo RP, Wright T, Rakela J, Levy G, Schiff E, Gish R, et al. A multicenter United States–Canadian trial to assess Lamivudine mono-therapy before and after liver transplantation for chronic hepatitis B. HEPATOLOGY 2001; 33: 424432.
  • 20
    Fontana RJ. Management of patients with decompensated HBV cirrhosis. Semin Liver Dis 2003; 23: 89100.
  • 21
    Dienstag JL, Goldin RD, Heathcote EJ, Hann HW, Woessner M, Stephenson SL, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology. 2003; 124: 105117.
  • 22
    Marcellin P, Lau GK, Bonino F, Farci P, Hadziyannis S, Jin R, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 12061217.
  • 23
    Adefovir Dipivoxil 438 Study Group. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005; 352: 26732681.
  • 24
    Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, et al. A comparison of entecavir and lamivudine for HBeAg positive chronic hepatitis B. N Engl J Med 2006; 354: 10011010.
  • 25
    Lai CL, Yuen MF. The natural history and treatment of chronic hepatitis B: a critical evaluation of standard treatment criteria and end points. Ann Intern Med 2007; 147: 5861.
  • 26
    Kim HC, Nam CM, Jee SH, Han KH, Oh DK, Suh I. Normal serum aminotransferase concentration and risk of mortality from liver diseases: prospective cohort study. BMJ 2004; 328: 983986.
  • 27
    Ballmer PE, Walshe D, McNurlan MA, Watson H, Brunt PW, Garlick PJ. Albumin synthesis rates in cirrhosis: correlation with Child-Turcotte classification. HEPATOLOGY 1993; 18: 292297
  • 28
    Ono E, Shiratori Y, Okudaira T, Imamura M, Teratani T, Kanai F, ET AL. Platelet count reflects stage of chronic hepatitis C. Hepatol Res 1999; 15: 192200.
  • 29
    Lee TH, Kim WR, Benson JT, Therneau TM, Melton LJ 3rd. Serum aminotransferase activity and mortality risk in a United States community. HEPATOLOGY 2008; 47: 880887.
  • 30
    Tong MJ, Blatt LM, Kao JH, Cheng JT, Corey WG. Basal core promoter T1762/A1764 and precore A1896 gene mutations in HBsAg-positive hepatocellular carcinoma: a comparison to chronic carriers. Liver Int 2007; 73: 14781485.
  • 31
    Fang ZL, Ling R, Wang SS, Nong J, Huang CS, Harrison TJ. HBV core promoter mutations prevail in patients with hepatocellular carcinoma from Guangxi, China. J Med Virol 1998; 56: 1824.
  • 32
    Yotsuyanagi H, Hino K, Tomita E, Toyoda J, Yasuda K, Iino S. Precore and core promoter mutations, hepatitis B virus DNA levels and progressive liver injury in chronic hepatitis B. J Hepatol 2002; 37: 355363.
  • 33
    Yuen MF, Sablon E, Yuan HJ, Hui CK, Wong DK, Doutreloigne J, et al. Relationship between the development of precore and core promoter mutations and hepatitis B e antigen seroconversion in patients with chronic hepatitis B virus. J Infect Dis 2002; 186: 13351338.
  • 34
    Chu CJ, Keeffe EB, Han SH, Perrillo RP, Min AD, Soldevila-Pico C, et al. Prevalence of HBV precore/core promoter variants in the United States. HEPATOLOGY 2003; 38: 619628.
  • 35
    Carman WF, Jacyna MR, Hadziyannis S, Karayiannis P, McGarvey MJ, Makris A, et al. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 1989; 2: 588591.